v3.26.1
Research and Collaboration Arrangements (Tables)
6 Months Ended
Jun. 30, 2026
Research And Collaboration Arrangements [Abstract]  
Summary of Collaboration and License Revenue and Deferred Revenue

Collaboration and license revenue for each period was as follows (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Otsuka Pharmaceutical Co., Ltd.

 

$

3,691

 

 

$

 

 

$

6,648

 

 

$

 

Cystic Fibrosis Foundation

 

 

90

 

 

 

15

 

 

 

180

 

 

 

29

 

Total revenue

 

$

3,781

 

 

$

15

 

 

$

6,828

 

 

$

29

 

 

Deferred revenue is summarized as follows (in thousands):

 

 

June 30,
2026

 

 

December 31,
2025

 

Otsuka Pharmaceutical Co., Ltd.

 

$

2,390

 

 

$

 

Cystic Fibrosis Foundation

 

 

925

 

 

 

1,105

 

Total deferred revenue

 

$

3,315

 

 

$

1,105